176 related articles for article (PubMed ID: 2058083)
41. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
[TBL] [Abstract][Full Text] [Related]
42. The impact of megakaryocyte proliferation of the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukaemia.
Buhr T; Choritz H; Georgii A
Virchows Arch A Pathol Anat Histopathol; 1992; 420(6):473-8. PubMed ID: 1609507
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
44. Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders.
Lichtman MA
Leukemia; 2005 Jul; 19(7):1139-41. PubMed ID: 15902283
[No Abstract] [Full Text] [Related]
45. Chronic megakaryocytic granulocytic myelosis-CMGM. A subtype of chronic myeloid leukemia.
Georgii A; Vykoupil KF; Thiele J
Virchows Arch A Pathol Anat Histol; 1980; 389(3):253-68. PubMed ID: 6935864
[TBL] [Abstract][Full Text] [Related]
46. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF.
Li Y; Hetet G; Maurer AM; Chait Y; Dhermy D; Briere J
Br J Haematol; 1994 Jul; 87(3):471-6. PubMed ID: 7993786
[TBL] [Abstract][Full Text] [Related]
47. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Nakata Y
Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
[TBL] [Abstract][Full Text] [Related]
48. Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders.
Pajor L; Lacza A; Kereskai L; Jáksó P; Egyed M; Iványi JL; Radványi G; Dombi P; Pál K; Losonczy H
Mod Pathol; 2004 Dec; 17(12):1521-30. PubMed ID: 15257312
[TBL] [Abstract][Full Text] [Related]
49. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Hyun BH; Gulati GL; Ashton JK
Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
[TBL] [Abstract][Full Text] [Related]
50. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
51. Endomitotic index of megakaryocytes measured by flow cytometry helps to diagnose hematological disorders with abnormal platelet counts.
Baatout S; Chatelain B; Staquet P; Symann M; Chatelain C
Anticancer Res; 1998; 18(5A):3347-53. PubMed ID: 9858907
[TBL] [Abstract][Full Text] [Related]
52. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders.
Gaidano G; Guerrasio A; Serra A; Rege-Cambrin G; Saglio G
Leukemia; 1994 Apr; 8 Suppl 1():S27-9. PubMed ID: 8152300
[TBL] [Abstract][Full Text] [Related]
53. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
54. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
55. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
56. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases].
Seewann HL
Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009
[TBL] [Abstract][Full Text] [Related]
57. Microplanimetric studies on megakaryocytes in chronic granulocytic leukaemia and polycythaemia vera.
FRANZEN S; STRENGER G; ZAJICEK J
Acta Haematol; 1961; 26():182-93. PubMed ID: 13894731
[No Abstract] [Full Text] [Related]
58. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
59. Megakaryopoiesis in chronic myeloproliferative disorders: immunohistochemical evaluation of endoreduplicative activity by PCNA-staining reaction.
Thiele J; Titius BR; Kvasnicka HM; Rechmeier W; Fischer R
Anal Cell Pathol; 1994 Jul; 7(1):63-75. PubMed ID: 7981137
[TBL] [Abstract][Full Text] [Related]
60. Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythaemia and allied diseases.
Branehög I; Ridell B; Swolin B; Weinfeld A
Scand J Haematol; 1975 Dec; 15(5):321-32. PubMed ID: 1060175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
